Beruflich Dokumente
Kultur Dokumente
Akira Monji, MD, PhD,* Takahiro Kato, MD, PhD and Shigenobu Kanba, MD, PhD
Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
The etiology of schizophrenia remains unclear, while there has been a growing amount of evidence for the neuroinammation and immunogenetics, which are characterized by an increased serum concentration of several pro-inammatory cytokines. Despite the fact that microglia comprise only <10% of the total brain cells, microglia respond rapidly to even minor pathological changes in the brain and may contribute directly to the neuronal degeneration by producing various pro-inammatory cytokines and free radicals. In many aspects, the neuropathology of schizophrenia has recently been reported to be closely associatedwith microglial activation. Previous studies have
shown the inhibitory effects of some typical/atypical antipsychotics on the release of inammatory cytokines and free radicals from activated microglia, both of which have recently been known to cause a decrease in neurogenesis as well as white matter abnormalities in the brains of patients with schizophrenia. The microglia hypothesis of schizophrenia may shed new light on the therapeutic strategy for schizophrenia. Key words: antipsychotics, cytokine, inammation, microglia, schizophrenia.
CHIZOPHRENIA IS A chronic and often debilitating illness that affects approximately 1% of the world population. In addition to severely disrupting the life of patients and their families, schizophrenia imposes a great cost on society in terms of productivity loss and treatment-related expenses.1,2 The etiology of schizophrenia remains elusive, while dopaminergic hyperfunction in the limbic system and dopaminergic hypofunction in the frontal cortex as well as glutamatergic hypofunction are known to play important roles in the pathophysiology of schizophrenia.
We herein review the relationship between cytokines and schizophrenia. We also propose the microglia hypothesis of schizophrenia (Fig. 1), and suggest a therapeutic strategy for schizophrenia through the inhibition of microglial activation.
*Correspondence: Akira Monji, MD, PhD, Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan. Email: amonji@hf.rim.or.jp Accepted 27 January 2009.
2009 The Authors Journal compilation 2009 Japanese Society of Psychiatry and Neurology
257
258
A. Monji et al.
Activated microglia
Cytokines TNF- IL-1 IL-6 etc Free Radicals Nitric Oxide (NO) Superoxide (O2-) Peroxynitrite (ONOO-) etc
Pathophysiology of Schizophrenia
Figure 1. Microglia hypothesis of schizophrenia. Immunological/inammatory activators such as interferon (IFN)-g and lipopolysaccharide (LPS), which are induced by varieties of stress events and life events, activate microglia in the central nervous system. Activated microglia release pro-inammatory cytokines and free radicals. These mediators are known to cause neuronal degeneration, white matter abnormalities and decreased neurogenesis. These neuronmicroglia interactions may thus be one of the important factors in the pathophysiology of schizophrenia. IL, interleukin; TNF, tumor necrosis factor.
-3, -4, -6, -10, -12, -15, and -18, transforming growth factor-b (TGF-b), colony-stimulating factors such as macrophage colony-stimulating factor (M-CSF), platelet-derived growth factor (PDG), epidermal growth factor (EGF), broblast growth factor (FGF), insulin-like growth factor (IGF), and neurotrophic factors such as nerve growth factor (NGF), brainderived neurotrophic factor (BDNF), and neurotrophins (NT-3 and NT-4). An increasing body of evidence relates to the evergrowing family of chemokines. Neurodevelopmental roles are postulated for various cytokines. Some also modulate neuronal activities in the mature CNS and participate in
neuro-immuneendocrine communication. Constitutive functions of typical immunoregulators in the day-to-day physiology of the normal immuneprivileged CNS are still unclear, while certain cytokines appear in the affected brain region and the cerebrospinal uid (CSF) when the CNS homeostasis is disturbed as a result of trauma, stroke, ischemia, infection, or degenerative processes. Increased cytokine levels in the CNS may result from bloodbrain barrier (BBB) disruption or synthesis by invading immune cells, both of which originate from extraneuronal sources. Nevertheless, most, if not all, neuropathologies are to various extents associated with the
2009 The Authors Journal compilation 2009 Japanese Society of Psychiatry and Neurology
259
activation of microglia and astrocytes. Microglia are the primary reservoirs of pro-inammatory cytokines such as IL-6, TNF-a and IFN-g and act as antigenpresenting cells in the CNS.4 Despite the fact that microglia comprise only <10% of the total brain cells, microglia respond rapidly to even minor pathological changes in the brain and may contribute directly to neuronal degeneration by producing various pro-inammatory cytokines and free radicals.5,6 In contrast, the neuron microglia interaction has been reported to orchestrate the balance between synaptogenesis and neuronal death during the brains development and injuries.7
2009 The Authors Journal compilation 2009 Japanese Society of Psychiatry and Neurology
260
A. Monji et al.
cell proliferation in the dentate gyrus of NPAS3 gene-decient mice has been found to be reduced signicantly, which indicated impaired neurogenesis involved in schizophrenia.37 Disruptedin-schizophrenia 1 (DISC1) is a well-known schizophrenia susceptibility gene. A recent study has shown that DISC1 regulates integration of newly generated neurons in the adult brain.38 The aforementioned results indicate the close relationship between schizophrenia and neurogenesis. With regard to neurogenesis, atypical antipsychotics, but not typical antipsychotics, induced neurogenesis in the adult brains of rodents.35,39,40 In contrast, CNS inammation is detrimental for adult hippocampal neurogenesis.41,42 The negative effects of inammation on differentiation and survival of the neuronal cells are due, in vitro, to microglia-derived TNF-a and nitric oxide (NO).41,43 Pro-inammatory cytokines such as Il-1b and TNF-a have been reported to inhibit neurogenesis in vivo.44,45 In addition, in vivo, neurogenesis can be restored by anti-inammatory drugs such as minocycline and indomethacin that inhibit microglial activation.41,42
cause elimination without cell death.50,51 Inappropriate activation of apoptosis occurs not only in the neurons, but also in the oligodendrocytes and synapses.50 Pro-inammatory cytokines such as TNF-a have been well characterized as mediators of oxidative stress, and they induced apoptosis in human cortical neuron as well as oligodendrocytes.52,53 In addition, NO has been reported not only to directly induce neuronal apoptosis, but also to be involved in cytokine-mediated neuronal apoptosis.54,55 The interaction between NO and superoxide anion (O2-), which can be generated from activated microglia, forms peroxynitrite (ONOO-). Peroxynitrite is highly toxic and triggers apoptotic cell death. Moreover, high levels of NO and TNF-a may also affect synaptogenesis, synaptic plasticity and connectivity, and the composition of synaptic membranes.56,57 The alteration in the synaptic organization of the brain is one of the key features of schizophrenia.58
2009 The Authors Journal compilation 2009 Japanese Society of Psychiatry and Neurology
261
nia.74,75 We thus hypothesize that antipsychotics may have anti-inammatory effects on microglial activation.
Cell line (6-3) Primary culture Cell line (BV-2) Primary culture
ATP, adenyl triphosphate; IFN-g, interferon-g; IL, interleukin; LPS, lipopolysaccharide; TNF, tumor necrosis factor.
2009 The Authors Journal compilation 2009 Japanese Society of Psychiatry and Neurology
262
A. Monji et al.
atypical antipsychotics such as perospirone and quetiapine.81 There have been some reports that suggested a relationship between schizophrenia and IFN-g, a major immunoactivator in the CNS. The most important immunological studies in schizophrenia have shown that a shift from T-helper 1 (Th1)-like cellular to Th2-like humoral immune reactivity is the most characteristic common immune nding and these studies have suggested a blunted IFN-g signal in schizophrenia.84 Rothermundt et al., however, have argued that the reduced IFN-g production in vitro may reect an increased production in vivo, because it is found in several autoimmune disorders.85 Furthermore, the serum levels of IL-2 and IFN-g, and the production of these cytokines from the peripheral blood mononuclear cells stimulated by phytohemagglutinin have been reported to be signicantly higher in schizophrenia patients than in controls.86 Furthermore, a recent systematic quantitative review on the inammatory cytokine alterations in schizophrenia did not support the Th2 shift hypothesis of schizophrenia.11 Spiperone, a typical antipsychotic, also inhibited the production of NO and pro-inammatory cytokines such as IL-1b and TNF-a from activated microglia, while spiperone was neuroprotective, because the drug reduced microglia-mediated neuroblastoma cell death in the microglia/neuron co-culture.83
Perspective
All of these studies suggest that some antipsychotics may therefore have a potentially useful therapeutic effect on patients with schizophrenia by reducing microglial inammatory reactions, which may cause the apoptotic process, the inhibition of neurogenesis, and the white matter abnormalities in the brains of patients with schizophrenia. This is consistent with the evidence showing antipsychotics inuence on slowing the progressive reduction in cortical gray matter in schizophrenia.72 In contrast, microglia can secrete neurotrophic factors other than proinammatory cytokines and free radicals such as BDNF. A recent study has shown that a7 nicotinic acetylcholine receptor agonist (a7nAChR) can modify microglial activation into a neuroprotective role by suppressing the inammatory state and strengthening the protective function.89 These results are very interesting because some a7nAChR agonists are known to improve the cognitive dysfunction of schizophrenia.90 The appropriate control of microglial activation may thus be a promising therapeutic target for schizophrenia. Pro-inammatory cytokines are also known to play important roles in the pathophysiology of depression.91 Etanercept, which is a soluble TNF-a receptor that prevents TNF-amediated response, has recently been reported to relieve fatigue and symptoms of depression with psoriasis.92 Immnosuppression or immunomodulatory drugs may thus be benecial at least for the treatment of acute schizophrenia.93
CONCLUSIONS
In many aspects the neuropathology of schizophrenia is closely associated with microglial activation. We and other researchers have shown the inhibitory effects of some typical or atypical antipsychotics on the release of inammatory cytokines and free radicals from activated microglia. Our microglia hypothesis of schizophrenia (Fig. 1) may shed new light on the therapeutic strategy for schizophrenia.
REFERENCES
1 Koyama A, Ito H, Nakanishi M, Sawamura K, Higuchi T. Addition of antipsychotics to medication regimens during schizophrenic inpatient care. Psychiatry Clin. Neurosci. 2008; 62: 5664. 2 Chien IC, Hsu JH, Bih SH et al. Prevalence, correlates, and disease patterns of antipsychotic use in Taiwan. Psychiatry Clin. Neurosci. 2008; 62: 677684.
2009 The Authors Journal compilation 2009 Japanese Society of Psychiatry and Neurology
263
3 Ozbey U, Tug E, Kara M, Namli M. The value of interleukin-12B (p40) gene promoter polymorphism in patients with schizophrenia in a region of East Turkey. Psychiatry Clin. Neurosci. 2008; 62: 307312. 4 Bessis A, Bechade C, Bernard D, Roumier A. Microglial control of neuronal death and synaptic properties. Glia 2007; 55: 233238. 5 Ogawa K, Yamada T, Tsujioka Y et al. Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimers disease and Parkinsons disease. Psychiatry Clin. Neurosci. 2000; 54: 419426. 6 Ishizuka K, Kimura T, Igata R, Katsuragi S, Takamatsu J, Miyakawa T. Identication of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimers disease. Psychiatry Clin. Neurosci. 1997; 51: 135138. 7 Hanisch U. Microglia as a source and target of cytokines. Glia 2002; 40: 140155. 8 Arion D, Unger T, Lewis DA, Levitt P, Mirnics K. Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol. Psychiatry 2007; 62: 711721. 9 Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav. Immun. 2006; 20: 532545. 10 Narayan S, Tang B, Head SR et al. Molecular proles of schizophrenia in the CNS at different stages of illness. Brain Res. 2008; 1239: 235248. 11 Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inammatory cytokine alterations in schizophrenia: A systematic quantitative review. Biol. Psychiatry 2008; 63: 801808. 12 Sperner-Unterweger B. Immunological aetiology of major psychiatric disorders: Evidence and therapeutic implications. Drugs 2005; 65: 14931520. 13 Lin A, Kenis G, Bignotti S et al. The inammatory response system in treatment-resistant schizophrenia: Increased serum interleukin-6. Schizophr. Res. 1998; 32: 915. 14 Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: Relationship to outcome in schizophrenia. J. Clin. Psychiatry 2004; 65: 940947. 15 Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial. Schizophr. Res. 2007; 90: 179185. 16 Muller N, Riedel M, Schwarz MJ, Engel RR. Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2005; 255: 149151. 17 Schmitt A, Bertsch T, Henning U et al. Increased serum S100B in elderly, chronic schizophrenic patients: Negative correlation with decit symptoms. Schizophr. Res. 2005; 80: 305313. 18 Ashdown H, Dumont Y, Ng M, Poole S, Boksa P, Luheshi GN. The role of cytokines in mediating effects of prenatal
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
infection on the fetus: Implications for schizophrenia. Mol. Psychiatry 2006; 11: 4755. Nawa H, Takei N. Recent progress in animal modeling of immune inammatory processes in schizophrenia: Implication of specic cytokines. Neurosci. Res. 2006; 56: 213. Nurun BN, Tanaka T, Kamino K et al. Toll-like receptor 3 mediated hyperphosphorylation of tau in human SH-SY5Y neuroblastoma cells. Psychiatry Clin. Neurosci. 2006; 60: S27S33. Block ML, Hong JS. Microglia and inammation-mediated neurodegeneration: Multiple triggers with a common mechanism. Prog. Neurobiol. 2005; 76: 7798. Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol. Psychiatry 1999; 46: 729739. Perez-Neri I, Ramirez-Bermudez J, Montes S, Rios C. Possible mechanisms of neurodegeneration in schizophrenia. Neurochem. Res. 2006; 31: 12791294. Nakki R, Koistinaho J, Sharp FR, Sagar SM. Cerebellar toxicity of phencyclidine. J. Neurosci. 1995; 15: 2097 2108. Nakki R, Nickolenko J, Chang J, Sagar SM, Sharp FR. Haloperidol prevents ketamine- and phencyclidine-induced HSP70 protein expression but not microglial activation. Exp. Neurol. 1996; 137: 234241. Bayer TA, Buslei R, Havas L, Falkai P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci. Lett. 1999; 271: 126128. Radewicz K, Garey LJ, Gentleman SM, Reynolds R. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J. Neuropathol. Exp. Neurol. 2000; 59: 137150. Steiner J, Mawrin C, Ziegeler A et al. Distribution of HLADR-positive microglia in schizophrenia reects impaired cerebral lateralization. Acta Neuropathol. 2006; 112: 305 316. Steiner J, Bielau H, Brisch R et al. Immunological aspects in the neurobiology of suicide: Elevated microglial density in schizophrenia and depression is associated with suicide. J. Psychiatr. Res. 2008; 42: 151157. Cagnin A, Kassiou M, Meikle SR, Banati RB. In vivo evidence for microglial activation in neurodegenerative dementia. Acta Neurol. Scand. Suppl. 2006; 185: 107114. Berckel BN, Bossong MG, Boellaard R et al. Microglia activation in recent-onset schizophrenia: A quantitative (R)[11C]PK11195 positron emission tomography study. Biol. Psychiatry 2008; 64: 820822. Warner-Schmidt JL, Duman RS. Hippocampal neurogenesis: Opposing effects of stress and antidepressant treatment. Hippocampus 2006; 16: 239249. Reif A, Fritzen S, Finger M et al. Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol. Psychiatry 2006; 11: 514522. Liu J, Suzuki T, Seki T, Namba T, Tanimura A, Arai H. Effects of repeated phencyclidine administration on adult
2009 The Authors Journal compilation 2009 Japanese Society of Psychiatry and Neurology
264
A. Monji et al.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
hippocampal neurogenesis in the rat. Synapse 2006; 60: 5668. Maeda K, Sugino H, Hirose T et al. Clozapine prevents a decrease in neurogenesis in mice repeatedly treated with phencyclidine. J. Pharmacol. Sci. 2007; 103: 299308. Pickard BS, Pieper AA, Porteous DJ, Blackwood DH, Muir WJ. The NPAS3 gene: Emerging evidence for a role in psychiatric illness. Ann. Med. 2006; 38: 439448. Pieper AA, Wu X, Han TW et al. The neuronal PAS domain protein 3 transcription factor controls FGF-mediated adult hippocampal neurogenesis in mice. Proc. Natl Acad. Sci. USA 2005; 102: 1405214057. Duan X, Chang JH, Ge S et al. Disrupted-In-Schizophrenia 1 regulates integration of newly generated neurons in the adult brain. Cell 2007; 130: 11461158. Wakade CG, Mahadik SP, Waller JL, Chiu FC. Atypical neuroleptics stimulate neurogenesis in adult rat brain. J. Neurosci. Res. 2002; 69: 7279. Kodama M, Fujioka T, Duman RS. Chronic olanzapine or uoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol. Psychiatry 2004; 56: 570580. Monje ML, Toda H, Palmer TD. Inammatory blockade restores adult hippocampal neurogenesis. Science 2003; 302: 17601765. Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O. Inammation is detrimental for neurogenesis in adult brain. Proc. Natl Acad. Sci. USA 2003; 100: 1363213637. Cacci E, Claasen JH, Kokaia Z. Microglia-derived tumor necrosis factor-alpha exaggerates death of newborn hippocampal progenitor cells in vitro. J. Neurosci. Res. 2005; 80: 789797. Iosif RE, Ekdahl CT, Ahlenius H et al. Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J. Neurosci. 2006; 26: 97039712. Kaneko N, Kudo K, Mabuchi T et al. Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. Neuropsychopharmacology 2006; 31: 26192626. Davis KL, Stewart DG, Friedman JI et al. White matter changes in schizophrenia: Evidence for myelin-related dysfunction. Arch. Gen. Psychiatry 2003; 60: 443456. Kumra S, Ashtari M, Cervellione KL et al. White matter abnormalities in early-onset schizophrenia: A voxel-based diffusion tensor imaging study. J. Am. Acad. Child Adolesc. Psychiatry 2005; 44: 934941. Salisbury DF, Kuroki N, Kasai K, Shenton ME, McCarley RW. Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Arch. Gen. Psychiatry 2007; 64: 521529. Hulshoff Pol HE, Kahn RS. What happens after the rst episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr. Bull. 2008; 34: 354366.
50 Glantz LA, Gilmore JH, Lieberman JA, Jarskog LF. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr. Res. 2006; 81: 4763. 51 Jarskog LF, Glantz LA, Gilmore JH, Lieberman JA. Apoptotic mechanisms in the pathophysiology of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005; 29: 846858. 52 Medina S, Martinez M, Hernanz A. Antioxidants inhibit the human cortical neuron apoptosis induced by hydrogen peroxide, tumor necrosis factor alpha, dopamine and beta-amyloid peptide 1-42. Free Radic. Res. 2002; 36: 11791184. 53 Buntinx M, Moreels M, Vandenabeele F et al. Cytokineinduced cell death in human oligodendroglial cell lines: I. Synergistic effects of IFN-gamma and TNF-alpha on apoptosis. J. Neurosci. Res. 2004; 76: 834845. 54 Palluy O, Rigaud M. Nitric oxide induces cultured cortical neuron apoptosis. Neurosci. Lett. 1996; 208: 14. 55 Hu S, Peterson PK, Chao CC. Cytokine-mediated neuronal apoptosis. Neurochem. Int. 1997; 30: 427431. 56 Sunico CR, Portillo F, Gonzalez-Forero D, Moreno-Lopez B. Nitric-oxide-directed synaptic remodeling in the adult mammal CNS. J. Neurosci. 2005; 25: 14481458. 57 Stellwagen D, Malenka RC. Synaptic scaling mediated by glial TNF-alpha. Nature 2006; 440: 10541059. 58 Roberts RC, Roche JK, Conley RR. Synaptic differences in the postmortem striatum of subjects with schizophrenia: A stereological ultrastructural analysis. Synapse 2005; 56: 185197. 59 Price G, Cercignani M, Bagary MS et al. A volumetric MRI and magnetization transfer imaging follow-up study of patients with rst-episode schizophrenia. Schizophr. Res. 2006; 87: 100108. 60 Schlosser RG, Nenadic I, Wagner G et al. White matter abnormalities and brain activation in schizophrenia: A combined DTI and fMRI study. Schizophr. Res. 2007; 89: 111. 61 Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: A study from the Stanley Neuropathology Consortium. Schizophr. Res. 2004; 67: 269275. 62 Uranova NA, Vostrikov VM, Vikhreva OV, Zimina IS, Kolomeets NS, Orlovskaya DD. The role of oligodendrocyte pathology in schizophrenia. Int. J. Neuropsychopharmacol. 2007; 10: 537545. 63 Iwamoto K, Ueda J, Bundo M, Nakano Y, Kato T. Effect of a functional single nucleotide polymorphism in the 2,3cyclic nucleotide 3-phosphodiesterase gene on the expression of oligodendrocyte-related genes in schizophrenia. Psychiatry Clin. Neurosci. 2008; 62: 103108. 64 McCullumsmith RE, Gupta D, Beneyto M et al. Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia. Schizophr. Res. 2007; 90: 1527.
2009 The Authors Journal compilation 2009 Japanese Society of Psychiatry and Neurology
265
65 Li J, Baud O, Vartanian T, Volpe JJ, Rosenberg PA. Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. Proc. Natl Acad. Sci. USA 2005; 102: 99369941. 66 Merrill JE, Ignarro LJ, Sherman MP, Melinek J, Lane TE. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J. Immunol. 1993; 151: 21322141. 67 Cammer W, Zhang H. Maturation of oligodendrocytes is more sensitive to TNF alpha than is survival of precursors and immature oligodendrocytes. J. Neuroimmunol. 1999; 97: 3742. 68 Feldhaus B, Dietzel ID, Heumann R, Berger R. Effects of interferon-gamma and tumor necrosis factor-alpha on survival and differentiation of oligodendrocyte progenitors. J. Soc. Gynecol. Invest. 2004; 11: 8996. 69 Lieberman JA, Tollefson GD, Charles C et al. Antipsychotic drug effects on brain morphology in rst-episode psychosis. Arch. Gen. Psychiatry 2005; 62: 361370. 70 Chakos MH, Schobel SA, Gu H et al. Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia. Br. J. Psychiatry 2005; 186: 2631. 71 Massana G, Salgado-Pineda P, Junque C et al. Volume changes in gray matter in rst-episode neuroleptic-naive schizophrenic patients treated with risperidone. J. Clin. Psychopharmacol. 2005; 25: 111117. 72 Girgis RR, Diwadkar VA, Nutche JJ, Sweeney JA, Keshavan MS, Hardan AY. Risperidone in rst-episode psychosis: A longitudinal, exploratory voxel-based morphometric study. Schizophr. Res. 2006; 82: 8994. 73 Lu LX, Guo SQ, Chen W, Li Q, Cheng J, Guo JH. Effect of clozapine and risperidone on serum cytokine levels in patients with rst-episode paranoid schizophrenia. Academic journal of the rst medical college of PLA. Di Yi Jun Yi Da Xue Xue Bao 2004; 24: 12511254 (in Chinese). 74 Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007; 31: 304307. 75 Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: An open-label study. Clin. Neuropharmacol. 2008; 31: 287292. 76 Kowalski J, Labuzek K, Herman ZS. Flupentixol and triuperidol reduce secretion of tumor necrosis factor-alpha and nitric oxide by rat microglial cells. Neurochem. Int. 2003; 43: 173178. 77 Kowalski J, Labuzek K, Herman ZS. Flupentixol and triuperidol reduce interleukin-1 beta and interleukin-2 release by rat mixed glial and microglial cell cultures. Pol. J. Pharmacol. 2004; 56: 563570. 78 Labuzek K, Kowalski J, Gabryel B, Herman ZS. Chlorpromazine and loxapine reduce interleukin-1beta and interleukin-2 release by rat mixed glial and microglial cell cultures. Eur. Neuropsychopharmacol. 2005; 15: 2330.
79 Hou Y, Wu CF, Yang JY et al. Effects of clozapine, olanzapine and haloperidol on nitric oxide production by lipopolysaccharide-activated N9 cells. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006; 30: 15231528. 80 Kato T, Monji A, Hashioka S, Kanba S. Risperidone signicantly inhibits interferon-gamma-induced microglial activation in vitro. Schizophr. Res. 2007; 92: 108115. 81 Bian Q, Kato T, Monji A et al. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008; 32: 4248. 82 Kato T, Mizoguchi Y, Monji A et al. Inhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca2+ regulation in vitro. J. Neurochem. 2008; 106: 815825. 83 Zheng LT, Hwang J, Ock J, Lee MG, Lee WH, Suk K. The antipsychotic spiperone attenuates inammatory response in cultured microglia via the reduction of proinammatory cytokine expression and nitric oxide production. J. Neurochem. 2008; 107: 12251235. 84 Schwarz MJ, Muller N, Riedel M, Ackenheil M. The Th2hypothesis of schizophrenia: A strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med. Hypotheses 2001; 56: 483486. 85 Rothermundt M, Arolt V, Bayer TA. Review of immunological and immunopathological ndings in schizophrenia. Brain Behav. Immun. 2001; 15: 319339. 86 Cazzullo CL, Sacchetti E, Galluzzo A et al. Cytokine proles in drug-naive schizophrenic patients. Schizophr. Res. 2001; 47: 293298. 87 Pocock JM, Kettenmann H. Neurotransmitter receptors on microglia. Trends Neurosci. 2007; 30: 527535. 88 Lu XH, Dwyer DS. Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin-sensitive pathways. J. Mol. Neurosci. 2005; 27: 43 64. 89 Suzuki T, Hide I, Matsubara A et al. Microglial alpha7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role. J. Neurosci. Res. 2006; 83: 14611470. 90 Lieberman JA, Javitch JA, Moore H. Cholinergic agonists as novel treatments for schizophrenia: The promise of rational drug development for psychiatry. Am. J. Psychiatry 2008; 165: 931936. 91 Raison CL, Capuron L, Miller AH. Cytokines sing the blues: Inammation and the pathogenesis of depression. Trends Immunol. 2006; 27: 2431. 92 Tyring S, Gottlieb A, Papp K et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Doubleblind placebo-controlled randomised phase III trial. Lancet 2006; 367: 2935. 93 Knight JG, Menkes DB, Highton J, Adams DD. Rationale for a trial of immunosuppressive therapy in acute schizophrenia. Mol. Psychiatry 2007; 12: 424431.
2009 The Authors Journal compilation 2009 Japanese Society of Psychiatry and Neurology